Here are three things to know.
1. According to Additive Orthopaedics’ vice president of engineering and operations Brian McLaughlin, the lattice structures have shown close to 90 percent bony in-growth after six months using no biologics.
2. Since its commercial launch in 2017, there have been more than 1,000 implantations of Additive Orthopaedics’ devices.
3. The company recently closed a series B funding round of $1 million.
More articles on surface technology:
4 things to know about the U.S. launch of K2M’s Mojave PL 3D Expandable Interbody System
3 things to know about Tiger Shark, ChoiceSpine’s new porous titanium interbody device
‘Nanotechnology is the way of the future’: Dr. David DeWitt on spinal implant nanosurface technology
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
